Consequences of estrogen deprivation and the rationale for hormone replacement therapy

American Journal of Managed Care

Volumn 6, Issue 14 SUPPL., 2000, Pages

  Hammond, C B ^a   Rackley, C E ^a   Fiorica, J ^a   Morrison, A ^a   Wysocki, S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ANTILIPEMIC AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM CHANNEL BLOCKING AGENT; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DHES; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; FLUOXETINE; GESTAGEN; LEVODOPA; PHYTOESTROGEN; PROBUCOL; QUERCETIN; RALOXIFENE; RESVERATROL; RETINOL; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOYBEAN PROTEIN; STATIN; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BONE METABOLISM; BREAST CANCER; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DIABETES MELLITUS; DYSKINESIA; ESTROGEN DEFICIENCY; FEMALE; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; POPULATION RISK; PRIORITY JOURNAL; TREATMENT OUTCOME;

ALZHEIMER DISEASE; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS; ESTROGEN REPLACEMENT THERAPY; EVALUATION STUDIES; FEMALE; HUMAN; MACULAR DEGENERATION; MANAGED CARE PROGRAMS; MENOPAUSE; MIDDLE AGE; OSTEOPOROSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 0033813738     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (117)

1. The perimenopausal state and incipient ovarian failure
2. Treatment of the postmenopausal woman: Where we are today
3. Effects of estrogen on memory function in surgically menopausal women
4. Fractures attributable to osteoporosis: Report from the National Osteoporosis Foundation
5. The incidence of clinical diagnosed vertebral factures: A population-based study in Rochester, Minnesota, 1985-89
6. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation
7. Effects of hormone therapy on bone mineral density
8. The menopause: Sex steroids and osteoporosis
9. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial
10. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women
11. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
12. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
13. Nasal calcitonin for treatment of established osteoporosis
14. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
15. Systemic osteoporosis and oral bone loss
16. Relationships between mandibular and skeletal bone in a population of normal women
17. Postmenopausal tooth loss. Contributions to endentulism by osteoporosis and cigarette smoking
18. Post-menopausal hormone use and tooth loss: A prospective study
19. The benefits of estrogen replacement therapy on oral health
20. Postmenopausal estrogen replacement and tooth retention
21. Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Study of the Osteoporotic Fractures Research Group
22. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
23. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: The Framingham Study
24. Postmenopausal oestrogen treatment and stroke: A prospective study
25. Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden
26. Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort
27. Prevalence of age-related maculopathy. The Beaver Dam Eye Study
28. Risk factors for neovascular age-related macular degeneration
29. Is there evidence of an estrogen effect on age-related lens opacities?
30. Estrogens and cataracts
31. Hormone replacement therapy, reproductive factors, and cataract
32. Risk factors for central retinal vein occlusion
33. Postmenopausal hormone use and risk for colorectal cancer and adenoma
34. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women
35. Cardiovascular disease in women
36. Atherogenesis in diabetes
37. A prospective study of maturity-onset diabetes and risk of coronary heart disease and stroke in women
38. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men?
39. Postmenopausal estrogens and risk of myocardial infarction in diabetic women
40. Estimated prevalence of Alzheimer's disease in the United States
41. Women and menopause: Beliefs, attitudes, and behaviors. The North American Menopause Society 1997 Menopause Survey
42. Alzheimer's disease care: Costs and potential savings
43. Menopause and estrogen replacement therapy in Parkinson's disease
44. The effect of estrogen replacement on early Parkinson's disease
45. Risk of venous thromboembolism in users of hormone replacement therapy
46. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
47. Effects on the cardiovascular system: Basic aspects
48. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women
49. A prospective study of postmenopausal estrogen therapy and coronary heart disease
50. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Programs Follow-up Study
51. Noncontraceptive estogens and mortality: Long-term follow-up of women in the Walnut Creek Study
52. Stroke incidence and risk factors for stroke in Copenhagen, Denmark
53. Postmenopausal estrogen use and mortality
54. Estrogen replacement therapy and protection from acute myocardial infarction
55. Systolic blood pressure and cardiovascular mortality among 13,740 Dutch women
56. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: Evidence from a national cohort
57. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement
58. The risk of myocardial infarction associated with the progestins in postmenopausal women
59. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women
60. Estrogen replacement and coronary artery disease. Effect on survival in post-menopausal women
61. Postmenopausal estrogen use and coronary atherosclerosis
62. Randomized trial of estrogen plus progestin for secondary prevention of corornary heart disease in post-menopausal women
63. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women
64. The antioxidant vitamins and cardiovascular disease
65. Vitamin E consumption and the risk of coronary disease in women
66. No effect of β-carotene supplementation on the susceptibility of low density lipoprotein to in vitro oxidation among hypercholesterolaemic, post-menopausal women
67. Collaborative overview of randomised trials of antiplatelet therapy-1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
68. Postmenopausal hormone therapy and mortality
69. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer
70. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy
71. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - Long term follow-up of a Swedish cohort
72. The influence of exogenous estrogen use on survival after diagnosis of endometrial cancer
73. Hormone replacement therapy for women with a past history of breast cancer
74. Hormone replacement therapy in breast cancer
75. Hormone replacement therapy after breast cancer
76. Hormone replacement therapy in previously treated breast cancer patients
77. A case-controlled study of combined continuous oestrogen-progestin replacement therapy among women with a personal history of breast cancer
78. Tamoxifen [package insert]
79. Are cardiovascular benefits associated with conjugated equine estrogen therapy and red wine consumption a result of the antioxidant properties of their components?
80. Soy phytoestrogens: What will be their role in postmenopausal hormone replacement therapy?
81. Osteoporosis and hip fracture
82. Risk factors for injurious falls: A prospective study
83. Better postural balance in elderly women
84. The brain: A new target for hormone replacement therapy?
85. Estrogen replacement therapy may protect against intellectual decline in postmenopausal women
86. Cognitive function in nondemented older women who took estrogen after menopause
87. Low-dose estrogen replacement therapy for Alzheimer's disease in women
88. Effect of estrogen replacement therapy on memory in women with Parkinson's disease
89. A meta-analysis of the effect of hormone replacement therapy upon depressed mood
90. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group
91. The inflammatory response system of brain: Implications for therapy of Alzheimer's and other neurodegenerative diseases
92. Inflammatory cytokines in the CNS: Possible role in the pathogenesis of neurodegenerative disorders and therapeutic implications
93. Vascular actions of estrogen and Alzheimer's disease
94. Estrogen replacement therapy and risk of Alzheimer's disease
95. Animal model of vascular inflammation
96. Vascular actions of estrogen and Alzheimer's disease
97. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease
98. Estrogen can down-regulate the human catechol-O-methyltransferase gene expression: Its implication in Parkinson's disease
99. Transdermal 17β-estradiol in postmenopausal parkinsonian patients
100. Pramipexole and levodopa pharmacokinetics following concomitant administration
101. An examination of male-female differences in progression and mortality of Parkinson's disease
102. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa